Media coverage about Steris (NYSE:STE) has trended somewhat positive on Saturday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Steris earned a news sentiment score of 0.19 on Accern’s scale. Accern also gave news headlines about the medical equipment provider an impact score of 46.528703024371 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the headlines that may have effected Accern’s scoring:
- Insider Selling: Steris PLC (STE) VP Sells 1,500 Shares of Stock (americanbankingnews.com)
- Financial Contrast: LivaNova (LIVN) and Steris (STE) (americanbankingnews.com)
- Northcoast Research Comments on Steris PLC’s Q3 2019 Earnings (STE) (americanbankingnews.com)
- FY2018 Earnings Forecast for Steris PLC Issued By KeyCorp (STE) (americanbankingnews.com)
- Steris PLC (STE) Receives Consensus Recommendation of “Buy” from Analysts (americanbankingnews.com)
STE has been the subject of a number of recent analyst reports. KeyCorp reissued an “overweight” rating and set a $101.00 target price (up from $91.00) on shares of Steris in a research note on Thursday, November 2nd. Zacks Investment Research lowered shares of Steris from a “buy” rating to a “sell” rating in a research note on Monday, November 6th. TD Securities boosted their target price on shares of Steris from C$14.00 to C$16.00 and gave the company a “buy” rating in a research note on Thursday, November 9th. Raymond James Financial reissued a “market perform” rating and set a $100.00 target price on shares of Steris in a research note on Wednesday, January 3rd. Finally, Northcoast Research set a $102.00 target price on shares of Steris and gave the company a “buy” rating in a research note on Thursday, February 8th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Steris presently has an average rating of “Buy” and an average price target of $84.80.
Steris (NYSE:STE) last issued its earnings results on Wednesday, February 7th. The medical equipment provider reported $1.12 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.07 by $0.05. The firm had revenue of $661.90 million during the quarter, compared to analyst estimates of $663.17 million. Steris had a net margin of 9.42% and a return on equity of 11.57%. The business’s revenue was up 2.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.98 earnings per share. equities analysts forecast that Steris will post 4.13 EPS for the current year.
In related news, VP Karen L. Burton sold 1,500 shares of the company’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $85.59, for a total value of $128,385.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Sudhir K. Pahwa sold 2,000 shares of the company’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $92.09, for a total transaction of $184,180.00. The disclosure for this sale can be found here. 2.55% of the stock is owned by corporate insiders.
WARNING: “Steris (STE) Earns Daily News Sentiment Score of 0.19” was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://stocknewstimes.com/2018/02/17/steris-ste-earns-daily-news-sentiment-score-of-0-19.html.
Steris Company Profile
STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.
Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.